Marizyme, Inc. (MRZM)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -34.08 Million USD | -51.25% |
| 2022 | -12.97 Million USD | -47.07% |
| 2021 | -8.82 Million USD | -52.1% |
| 2020 | -5.79 Million USD | -448.15% |
| 2019 | -1.05 Million USD | -328.13% |
| 2018 | -247.12 Thousand USD | -97.84% |
| 2017 | -124.91 Thousand USD | 31.3% |
| 2016 | -181.81 Thousand USD | 84.73% |
| 2015 | -1.19 Million USD | 2.91% |
| 2014 | -1.22 Million USD | 43.93% |
| 2013 | -2.18 Million USD | 80.01% |
| 2012 | -10.94 Million USD | -377.02% |
| 2011 | -2.29 Million USD | -12656.16% |
| 2010 | -17.98 Thousand USD | 6.65% |
| 2009 | -19.26 Thousand USD | 80.28% |
| 2008 | -97.66 Thousand USD | -195.35% |
| 2007 | -33.06 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -1.58 Million USD | -16.0% |
| 2024 Q1 | -1.37 Million USD | 82.96% |
| 2023 Q2 | -4.8 Million USD | -125.23% |
| 2023 Q3 | -4.85 Million USD | -1.11% |
| 2023 Q4 | -8.04 Million USD | -65.54% |
| 2023 Q1 | -2.13 Million USD | 0.5% |
| 2023 FY | -19.62 Million USD | -51.25% |
| 2022 FY | -12.97 Million USD | -47.07% |
| 2022 Q2 | -4.6 Million USD | -15.18% |
| 2022 Q1 | -3.99 Million USD | -35.85% |
| 2022 Q3 | -2.23 Million USD | 51.47% |
| 2022 Q4 | -2.14 Million USD | 4.0% |
| 2021 Q4 | -2.94 Million USD | -67.5% |
| 2021 FY | -8.82 Million USD | -52.1% |
| 2021 Q1 | -2.81 Million USD | 0.63% |
| 2021 Q2 | -2.45 Million USD | 12.59% |
| 2021 Q3 | -1.75 Million USD | 28.53% |
| 2020 Q1 | -471.37 Thousand USD | -93.58% |
| 2020 Q4 | -2.82 Million USD | -36.96% |
| 2020 Q3 | -2.06 Million USD | -374.82% |
| 2020 Q2 | -434.91 Thousand USD | 7.73% |
| 2020 FY | -5.79 Million USD | -448.15% |
| 2019 FY | -1.05 Million USD | -328.13% |
| 2019 Q4 | -243.49 Thousand USD | 52.12% |
| 2019 Q1 | -67.54 Thousand USD | -7.92% |
| 2019 Q2 | -237.36 Thousand USD | -251.41% |
| 2019 Q3 | -508.56 Thousand USD | -114.26% |
| 2018 Q3 | -70.62 Thousand USD | -2.74% |
| 2018 Q1 | -45.17 Thousand USD | 60.72% |
| 2018 FY | -247.12 Thousand USD | -97.84% |
| 2018 Q4 | -62.59 Thousand USD | 11.37% |
| 2018 Q2 | -68.73 Thousand USD | -52.14% |
| 2017 FY | -124.91 Thousand USD | 31.3% |
| 2017 Q3 | 11.65 Thousand USD | 228.79% |
| 2017 Q4 | -115.01 Thousand USD | -1086.87% |
| 2017 Q2 | -9049.00 USD | 16.05% |
| 2017 Q1 | -10.77 Thousand USD | 84.6% |
| 2016 FY | -181.81 Thousand USD | 84.73% |
| 2016 Q4 | -70 Thousand USD | 0.0% |
| 2016 Q1 | -40 Thousand USD | 0.0% |
| 2016 Q3 | -70 Thousand USD | -250.0% |
| 2016 Q2 | -20 Thousand USD | 50.0% |
| 2015 FY | -1.19 Million USD | 2.91% |
| 2014 FY | -1.22 Million USD | 43.93% |
| 2013 Q3 | -506.3 Thousand USD | 5.37% |
| 2013 Q2 | -535.05 Thousand USD | 72.95% |
| 2013 Q1 | -1.97 Million USD | 57.34% |
| 2013 Q4 | 832.03 Thousand USD | 264.33% |
| 2013 FY | -2.18 Million USD | 80.01% |
| 2012 Q3 | -1.8 Million USD | 31.98% |
| 2012 FY | -10.94 Million USD | -377.02% |
| 2012 Q4 | -4.63 Million USD | -156.74% |
| 2012 Q2 | -2.65 Million USD | 3.34% |
| 2012 Q1 | -2.74 Million USD | -8.88% |
| 2011 Q2 | -2.27 Million USD | -10.61% |
| 2011 Q1 | -2.05 Million USD | -946.14% |
| 2011 Q3 | -2.7 Million USD | -18.81% |
| 2011 FY | -2.29 Million USD | -12656.16% |
| 2011 Q4 | -2.52 Million USD | 6.82% |
| 2010 Q1 | -2079.00 USD | -126.22% |
| 2010 FY | -17.98 Thousand USD | 6.65% |
| 2010 Q4 | -196.91 Thousand USD | -1119.28% |
| 2010 Q3 | -16.15 Thousand USD | 21.22% |
| 2010 Q2 | -20.5 Thousand USD | -886.05% |
| 2009 FY | -19.26 Thousand USD | 80.28% |
| 2009 Q1 | 17.59 Thousand USD | 335.78% |
| 2009 Q2 | -6915.00 USD | -139.3% |
| 2009 Q4 | -919.00 USD | -139.44% |
| 2009 Q3 | 2330.00 USD | 133.69% |
| 2008 Q4 | -7463.00 USD | 66.01% |
| 2008 FY | -97.66 Thousand USD | -195.35% |
| 2008 Q1 | -27.34 Thousand USD | 3.58% |
| 2008 Q2 | -13.73 Thousand USD | 49.78% |
| 2008 Q3 | -21.95 Thousand USD | -59.88% |
| 2007 Q4 | -28.35 Thousand USD | -42.37% |
| 2007 Q1 | -10 Thousand USD | 0.0% |
| 2007 FY | -33.06 Thousand USD | 0.0% |
| 2007 Q2 | -21.62 Thousand USD | -116.27% |
| 2007 Q3 | -19.91 Thousand USD | 7.9% |
| 2006 Q4 | -10 Thousand USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -2452.473% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -575.719% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -90.993% |
| Nascent Biotech, Inc. | -2.22 Million USD | -1428.626% |
| Rebus Holdings, Inc. | -664 Thousand USD | -5033.511% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 141.644% |
| Qrons Inc. | -643.67 Thousand USD | -5195.593% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -8649.78% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 38.592% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -8104.149% |
| Skye Bioscience, Inc. | -13.67 Million USD | -149.32% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 52.516% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 793.547% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -12923.741% |
| SQZ Biotechnologies Company | -75.82 Million USD | 55.046% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -1095.805% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -2119.103% |
| Mesoblast Limited | -84.14 Million USD | 59.492% |
| Genus plc | 6.4 Million USD | 632.602% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 449.876% |
| Pharming Group N.V. | -4.87 Million USD | -598.559% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -1615.926% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -3559.786% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -308.222% |
| ContraFect Corporation | -56.88 Million USD | 40.082% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -648.377% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -2331.293% |
| IMV Inc. | -38.67 Million USD | 11.856% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -1139.132% |
| MultiCell Technologies, Inc. | -722.81 USD | -4715733.483% |
| ONE Bio Corp. | 13.68 Million USD | 349.142% |
| Accustem Sciences Inc. | -3.74 Million USD | -809.843% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 42.216% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -6956.344% |
| Q BioMed Inc. | -3.44 Million USD | -889.272% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 1062.896% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -1197.288% |
| Biomind Labs Inc. | -1 Million USD | -3276.23% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 37.993% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -1074.891% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -412.732% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -1728.313% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -113703.806% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -114.789% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -1663.756% |
| GB Sciences, Inc. | -1.42 Million USD | -2299.599% |
| Alpha Cognition Inc. | -9.7 Million USD | -251.205% |
| HST Global, Inc. | -140.9 Thousand USD | -24090.79% |
| CSL Limited | 3.7 Billion USD | 100.921% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -2930.166% |
| Halberd Corporation | -75.05 Thousand USD | -45318.409% |
| Enzolytics Inc. | -2.14 Million USD | -1486.305% |
| Agentix Corp. | -1.37 Million USD | -2384.882% |
| Resverlogix Corp. | -12.74 Million USD | -167.366% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -975.87% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 91.981% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -3164.992% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -1067.569% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -2058.255% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -901.079% |
| AVAX Technologies, Inc. | 6.69 Million USD | 609.295% |
| Zenith Capital Corp. | -8.94 Million USD | -281.153% |
| Genscript Biotech Corporation | -415.79 Million USD | 91.802% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -195563.372% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -1288.274% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -19774.414% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1600.282% |
| Kadimastem Ltd | -3.04 Million USD | -1021.175% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -3363.89% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -2613.895% |
| BioStem Technologies, Inc. | -7.77 Million USD | -338.188% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -18682.002% |
| LadRx Corporation | -3.82 Million USD | -791.471% |
| Cell Source, Inc. | -4.32 Million USD | -688.064% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -4862.008% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -4862.008% |
| NovAccess Global Inc. | -2.46 Million USD | -1281.833% |
| Affymax, Inc. | -15.04 Million USD | -126.549% |
| Itoco Inc. | -919.14 Thousand USD | -3608.523% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -704.228% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -2946.159% |
| Mobile Lads Corp. | -554.55 Thousand USD | -6046.698% |
| CytoDyn Inc. | -18.05 Million USD | -88.761% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -135325.173% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -15388.38% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -5935.971% |
| SYBLEU INC | -149.18 Thousand USD | -22749.253% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -1776.68% |
| International Stem Cell Corporation | -663 Thousand USD | -5041.254% |
| Bioxytran, Inc. | -3.82 Million USD | -792.283% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -64654.02% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -167483.658% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 6.01% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -2006.707% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -4532.359% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -995.677% |
| Neutra Corp. | -229.48 Thousand USD | -14753.419% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -94.347% |
| PureTech Health plc | -146.19 Million USD | 76.685% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -58.607% |
| IXICO plc | -1.43 Million USD | -2272.061% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -259.146% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 72.016% |
| CSL Limited | 3.81 Billion USD | 100.894% |
| Cellectis S.A. | -108.85 Million USD | 68.687% |